Beta Bionics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	100.25	65.12	12	0.18
Revenue Growth (YoY)	53.94%	442.93%	6601.12%	-
Cost of Revenue	44.71	29.24	5.69	-
Gross Profit	55.54	35.89	6.31	0.18
Selling, General & Admin	92.43	54.96	24.22	33.5
Research & Development	34.79	26.18	17.94	31.43
Operating Expenses	127.22	81.14	42.16	64.92
Operating Income	-71.68	-45.25	-35.85	-64.74
Interest Expense	-	-	-	-0.01
Interest & Investment Income	10.93	3.91	1.78	0.2
Other Non Operating Income (Expenses)	-12.45	-13.41	-10.03	0.91
EBT Excluding Unusual Items	-73.2	-54.76	-44.1	-63.65
Other Unusual Items	-	-	-	-1.1
Pretax Income	-73.2	-54.76	-44.1	-64.75
Net Income	-73.2	-54.76	-44.1	-64.75
Net Income to Common	-73.2	-54.76	-44.1	-64.75
Shares Outstanding (Basic)	41	6	5	5
Shares Outstanding (Diluted)	41	6	5	5
Shares Change (YoY)	536.74%	20.01%	6.13%	-
EPS (Basic)	-1.81	-8.60	-8.31	-12.96
EPS (Diluted)	-1.81	-8.60	-8.31	-12.96
Free Cash Flow	-56.22	-51.67	-32.85	-60.98
Free Cash Flow Per Share	-1.39	-8.12	-6.19	-12.20
Gross Margin	55.40%	55.11%	52.59%	100.00%
Operating Margin	-71.50%	-69.48%	-298.88%	-36169.83%
Profit Margin	-73.02%	-84.08%	-367.64%	-36173.74%
Free Cash Flow Margin	-56.08%	-79.34%	-273.84%	-34067.04%
EBITDA	-70.11	-44.1	-34.62	-63.4
EBITDA Margin	-69.93%	-67.72%	-288.65%	-
D&A For EBITDA	1.57	1.15	1.23	1.35
EBIT	-71.68	-45.25	-35.85	-64.74
EBIT Margin	-71.50%	-69.48%	-298.87%	-
Revenue as Reported	-	-	-	0.18

Updated Feb 17, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q